Latest News

Patients with Atopic Dermatitis Are More Susceptible to Developing Inflammatory Bowel Disease
Patients with Atopic Dermatitis Are More Susceptible to Developing Inflammatory Bowel Disease

December 18th 2024

In a meta-analysis of over 61 million participants, it was found that AD patients have a 37% risk of developing IBD and similar conditions.

ICYMI: FDA Approves Galderma's Nemolizumab for Moderate to Severe Atopic Dermatitis in Patients 12 and Older
ICYMI: FDA Approves Galderma's Nemolizumab for Moderate to Severe Atopic Dermatitis in Patients 12 and Older

December 16th 2024

FDA Approves Tapinarof Cream, 1% for Atopic Dermatitis in Patients 2 Years and Older
FDA Approves Tapinarof Cream, 1% for Atopic Dermatitis in Patients 2 Years and Older

December 16th 2024

Arcutis Submits sNDA for Roflumilast Cream 0.05% to FDA for Patients Ages 2 to 5 with Atopic Dermatitis
Arcutis Submits sNDA for Roflumilast Cream 0.05% to FDA for Patients Ages 2 to 5 with Atopic Dermatitis

December 16th 2024

2024 Key Insights: Atopic Dermatitis
2024 Key Insights: Atopic Dermatitis

December 13th 2024

Latest CME Events & Activities

21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

February 8, 2025

View More

Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis

View More

Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making

View More

Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis

View More

Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color

View More

Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach

View More

Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis

View More

Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis

View More

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

View More

‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis

View More

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

View More

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

View More

© 2024 MJH Life Sciences

All rights reserved.